Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 18,156
Companies: 1,062
Drugs tracked: 3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)

Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

BI 1015550, BI 1015550

BI 1015550, Placebo matching BI 1015550, BI 1015550

BI 1015550, Placebo matching nerandomilast (BI 1015550)

BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

BI 764198, Placebo matching BI 764198

BI 907828, BI 907828, BI 907828

BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

Jardiance 10 mg film-coated tablets, empagliflozin, Placebo matching empagliflozin, film-coated tablets

KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung

Metalyse 5 000 units (25 mg) powder for solution for injection

OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion

Placebo matching BI 1015550, BI 1015550, BI 1015550

Placebo matching BI 1291583, BI 1291583

Placebo matching to spesolimab

Spesolimab, Placebo matching to Spesolimab

Tecentriq 1 200 mg concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BI 764532, RoActemra 20 mg/mL concentrate for solution for infusion

Frequently asked questions